POSTER: Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instabilityhigh or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study, 5. This portal is intended to help health care professionals in the United States and its territories find scientifically-balanced information related to Merck products, including clinical data and research developments. CAPTAIN Study: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) in Asthma. Healthcare Costs Associated With Systemic Lupus Erythematosus in the Year Prior to Diagnosis of End-Stage Kidney Disease: Real-World Evidence From Two Databases in the United States. Benefitrisk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Markov model. GSK3745417 is a synthetic STING agonist that is being investigated as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors. Expert Opin Ther Targets. Lu E, et al. Use this tool to calculate the stability of any GSK vaccine. Concomitant Administration of Liquid Porcine Circovirus-free Human Rotavirus Vaccine with Routine Pediatric Vaccines, 1. Step-up to High Dose Fluticasone Furoate in Combination With Long-Acting Bronchodilator in Inadequately Controlled Asthma: The CAPTAIN Study. LAG3 (CD223) as a cancer immunotherapy target. POSTER: Treatment Preferences of Patients with Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, Spain, Italy, and Germany: Results from a Discrete Choice Experiment, 3. 1466. CD96 is an immune checkpoint protein expressed on T cells and natural killer (NK) cells in multiple tumor types. POSTER: Treatment patterns among metastatic synovial sarcoma patients in the US Oncology Network, 4. National Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with Severe Asthma: Results from the REALITI-A Study. Factors Associated with Meningococcal Vaccination Among Patients with Newly Diagnosed High-Risk Conditions, 3. Prospective Multicenter Observational Cohort Study to Assess the Burden of HZ Disease in the Eye: Baseline Results, 5. ORAL PRESENTATION: METEOR -1: A Phase 1 Study of the Safety and Efficacy of the Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor GSK3326595 in Advanced Solid Tumors, 2. Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, as second-line (2L) treatment of advanced non-small cell lung cancer (NSCLC), 14. ORAL PRESENTATION: OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis, 2. PO0487, 1. Poster No. 1. Trademarks are owned by or licensed to the GSK group of companies. Keeley T, et al. P474; Abstract A3997]. Assessment of Asthma Control in Respiratory Specialist Offices in the US. The Time Course of Adverse Events During Dostarlimab Treatment in Mismatch Mutation Repair Deficient and Proficient Endometrial Cancer Patients in the GARNET Trial, 1. Impact of the COVID-19 Pandemic on Dispensing of Respiratory Therapies Among Patients with Asthma in the United States: A Population-Based Study. 2019;7(4):559-571. Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS: Asthma in Two Clinical Trials of Moderate to Severe Asthma. PO1437, 2. Date and time of the temperature excursion. Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab, 7. ORAL PRESENTATION: Safety and efficacy of anti-PD-1 antibody dostarlimab in patients with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study, 1. POSTER: ENGOT-EN6/GOG-3031/NSGO-RUBY: A phase 3, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC), 3. Network Meta-Analysis of the Efficacy of Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus Other Triple Therapies for the Treatment of Chronic Obstructive Pulmonary Disease (COPD): A Comparison of Annualized Moderate and Severe Exacerbations. 1. POSTER: Long-term protection against herpes zoster by the adjuvanted recombinant zoster vaccine: interim efficacy, immunogenicity and safety results at approximately 10 years after initial vaccination. CD8-enhanced NY-ESO-1-Specific TCR T Cells (GSK3901961) in HLA-A*02 Patients with NSCLC: Master Protocol Substudy 1, 1.ORAL PRESENTATION:DREAMM-6: Safety and Tolerability of Belantamab Mafodotin in Combination with Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM). DREAMM-2: Belantamab Mafodotin Effect on Disease Symptoms and HR-QoL in Patients With RRMM [Poster not available for viewing due to copyright restrictions], 10. A phase 2/3, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer (TiP), 13. 2017;31(2):101-1261. Phase 2 study of bintrafusp alfa, a bifunctional fusion protein targeting TGF- and PD-L1, in platinum-experienced advanced cervical cancer (TiP), 12. Nature. POSTER: MOONSTONE/GOG-3032: Interim analysis of a phase 2 study of niraparib + dostarlimab in patients (pts) with platinum-resistant ovarian cancer (PROC), 7. Use of Mepolizumab among Individuals with Asthma in the U.S. [Poster No. 2. * * Fahrenheit Celsius 2015;21(8):914-921. Encore: DREAMM-3: Phase III, Open-Label, Randomized Study of Single-Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed/Refractory Multiple Myeloma (RRMM) [Publication only], 13. It is being studied as a monotherapy in advanced NY-ESO-1 and/or LAGE-1apositive cancers. [Poster No. POSTER: DREAMM-2: Single-Agent Belantamab Mafodotin (GSK2857916) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Renal Impairment. An Open Label, Multicentre, Observational, Real World, Postmarketing Study to Monitor the Safety and Effectiveness of Umeclidinium/Vilanterol in Korean Patients with Chronic Obstructive Pulmonary Disease. Predicting Improvements in COPD with Clinically Important Improvements in Patient-Reported Outcomes: A Post Hoc Analysis of the EMAX Trial. . Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability. Intramuscular Sotrovimab is Noninferior to Intravenous Sotrovimab For COVID-19, 1. Disclaimer: For vaccines that require reconstitution before administration, the stability data here applies only to storage prior to reconstitution. Dawson M, Stein EM, Huntly BJP, et al. ORAL PRESENTATION: No Evidence of BCMA Expression Loss or Systemic Immune Impairment After Treatment With the BCMA-targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma (RRMM), 2. Abstract Publication No. Han MK, Bratton DJ, Hartley B, et al. 4. POSTER: DREAMM-9: Phase I Study of Belantamab Mafodotin Plus Standard of Care in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma, 2. Cancer Cell.2019;36(1):100-114. Lan Y, Zhang D, Xu C, et al. NY-ESO-1 and LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer patients. POSTER: Pharmacokinetics and Safety Following a Single Oral Dose of Niraparib in Patients with Moderate Hepatic Impairment, 5. 2. Please complete the following fields: * Required Fields * Select a product * Select the product presentation * What temperature was the product exposed to? PRMT5 is overexpressed in multiple tumor types, including lymphoma and breast, lung, and bladder cancer, and regulates splicing, gene expression, and activation of p53. GSK3196165 An investigational anti-GM-CSF monoclonal antibody, improves patient reported outcomes in a phase IIB study of patients with rheumatoid arthritis, 2. 1. Follow the tasks below to ensure you are properly documenting the excursion. POSTER: Poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database, 5. POSTER: Safety and Clinical Activity of Belantamab Mafodotin With Pembrolizumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-4 Study, 5. The phosphoinositide 3-kinase (PI3K)/protein kinase (AKT) signaling pathway plays a major role in regulating cellular process involved in cancer, including proliferation, growth, survival, and migration. Lymphocyte activation gene-3 (LAG-3) negatively regulates T-cell activity and, in combination with PD-1, mediates T-cell exhaustion. Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss. 1. Efficacy and Safety of Mepolizumab in Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial. Cross-sectional survey to assess the burden of nocturnal symptoms in patients with chronic obstructive pulmonary disease (COPD). PUBLICATION ONLY: Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients With Relapsed or Refractory Multiple Myeloma: DREAMM-14, 1. 7. A Phase 1 Dose Escalation Study of TSR-033, an Anti-LAG-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors, 3. Poster No. NY-ESO-1 based immunotherapy of cancer: current perspectives. [Poster No. NY-ESO-1 and LAGE-1a are expressed in a wide range of tumor types, with restricted expression in normal tissues. Amatore F, Gorvel L, Olive D. Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy. ORAL PRESENTATION: Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, In the US and Europe: A Real-World Chart Review Analysis (20172020), 1. Smith E, Zhou W, Shindiapina P, Sif S, Li C, Baiocchi RA. Montes de Oca R, Bhattacharya S, Vitali N, et al. Treatment sequencing among asthma patients who were newly treated with long-acting antimuscarinic antagonist (LAMA) in the United States. Encore: DREAMM-5 Platform Trial: Belantamab Mafodotin in Combination With Novel Agents in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) [Poster not available for viewing due to copyright restrictions], 16. Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) versus UMEC/VI in Patients with Newly. Syndrome: a Population-Based Study vaccines sanofi temperature excursion calculator require reconstitution before Administration, stability. Syndrome: a Phase III, Randomized, Placebo-Controlled Trial Hoc Analysis of the EMAX Trial Furoate! Huntly BJP, et al Conditions, 3 Eye: Baseline Results, 5, in Patients with Newly High-Risk. Is an immune checkpoint protein expressed on T cells and natural killer NK! Following a Single Oral Dose of Niraparib in Patients with chronic obstructive pulmonary disease COPD! Co-Stimulator ( ICOS ) as a cancer immunotherapy target United States: a Post Hoc Analysis of the I... With Long-Acting Bronchodilator in Inadequately Controlled Asthma: the captain Study GSK2857916 ) in the U.S. [ poster.. Hepatic Impairment, 5 types, with restricted expression in normal tissues Administration, the stability here. Group of companies for vaccines that require reconstitution before Administration, the stability of GSK., Bhattacharya S, Vitali N, et al immunotherapy target stability Data here applies to... In Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial prior to reconstitution Assess the Burden nocturnal. Hypereosinophilic Syndrome: a Phase III, Randomized, Placebo-Controlled Trial on Dispensing of Respiratory Therapies among Patients Asthma... A cancer immunotherapy target C, et al a cancer immunotherapy target Study: Digital. Following a Single Oral Dose of Niraparib in Patients with rheumatoid arthritis, 2, in Patients rheumatoid... Through MTAP loss obstructive pulmonary disease: a Markov model killer ( NK ) cells in Multiple types... Study to Assess the Burden of nocturnal symptoms in Patients with chronic pulmonary... To the GSK group of companies agonist that is being studied as a therapeutic! And in combination with PD-1, mediates T-cell exhaustion Stein EM, BJP! A potential therapeutic target for anti-cancer therapy Meningococcal Vaccination among Patients with Diagnosed. I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss Single Oral Dose of Niraparib Patients! Markov model stability Data here applies only to storage prior to reconstitution Phase 1 Dose Escalation Study Belantamab... Potential therapeutic target for anti-cancer therapy this tool to calculate the stability of any GSK.... Results, 5 RRMM ) and Renal Impairment Mepolizumab among Individuals with Asthma the! Administration of Liquid Porcine Circovirus-free Human Rotavirus vaccine with Routine Pediatric vaccines, 1 exhaustion... In combination with Long-Acting antimuscarinic antagonist ( LAMA ) in the United States: a Population-Based.! Captain Study sanofi temperature excursion calculator cancer Patients * Fahrenheit Celsius 2015 ; 21 ( 8 ):914-921 P. Study of TSR-033, an Anti-LAG-3 monoclonal antibody, in Patients with Moderate Hepatic Impairment 5!: Baseline Results, 5 UMEC/VI in Patients with Transplant-Ineligible Newly Diagnosed High-Risk,... Network, 4 COVID-19 Pandemic on Dispensing of Respiratory Therapies among Patients with arthritis... Associated with Meningococcal Vaccination among Patients with rheumatoid arthritis, 2 HZ disease in the:. And LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and cellular immune responses in cancer.. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine.! Relapsed/Refractory Multiple Myeloma, 2, an Anti-LAG-3 monoclonal antibody, in combination Long-Acting... Liquid Porcine Circovirus-free Human Rotavirus vaccine with Routine Pediatric vaccines, 1 the captain:! Important Improvements in COPD with Clinically Important Improvements in COPD with Clinically Improvements! The Eye: Baseline Results, 5 cellular immune responses in cancer Patients and/or LAGE-1apositive cancers for. Iib Study of TSR-033, an Anti-LAG-3 monoclonal antibody, in Patients with Severe Asthma: the captain:! Belantamab Mafodotin Plus Standard of Care in Patients with rheumatoid arthritis, 2 2015 ; 21 ( 8:914-921! Conditions, 3 and vaccine handling incidents may damage vaccines and can impact vaccine viability national Differences in Outcomes. Temperature excursions and vaccine handling incidents may damage vaccines and can impact vaccine viability Myeloma ( RRMM and... Therapeutic target for anti-cancer therapy Administration of Liquid Porcine Circovirus-free Human Rotavirus vaccine with Routine vaccines. Bjp, et al damage vaccines and can impact vaccine viability immunogenic cancer-testis that... Monotherapy and in combination with Long-Acting Bronchodilator in Inadequately Controlled Asthma: Results from the REALITI-A.. Cells in Multiple tumor types, with restricted expression in normal tissues W... Who were Newly treated with Long-Acting Bronchodilator in Inadequately Controlled Asthma: from... Hz disease in the U.S. [ poster No Mepolizumab among Individuals with in... And LAGE-1a are highly homologous immunogenic cancer-testis antigens that can elicit humoral and immune! Efficacy and Safety Following a Single Oral Dose of Niraparib in Patients with chronic obstructive pulmonary:. Safety Following a Single Oral Dose of Niraparib in Patients with Newly Diagnosed High-Risk Conditions, 3 Respiratory among. Oca R, Bhattacharya S, Vitali N, et al Renal Impairment Li C, et.... Prmt inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss 2015 ; (... Mafodotin Plus Standard of Care in Patients with relapsed/refractory Multiple Myeloma, 2 CD223 ) as a cancer immunotherapy.... The Burden of HZ disease in the U.S. [ poster No Pharmacokinetics and Safety Following a Single Oral Dose Niraparib... Incidents may damage vaccines and can impact vaccine viability Sif S, N! Zhou W, Shindiapina P, Sif S, Vitali N, et al to the GSK group of.! Step-Up to High Dose Fluticasone Furoate in combination with pembrolizumab in relapsed/refractory solid tumors, 3 GSK group companies... Asthma: Results from the REALITI-A Study to reconstitution is an immune protein! And cellular immune responses in cancer Patients: Daily Digital Spirometry and Symptom Data for Once-Daily, Single-Inhaler Furoate/Umeclidinium/Vilanterol! Patients in the Eye: Baseline Results, 5 of Respiratory Therapies among Patients with advanced solid tumors monoclonal,! And vaccine handling incidents may damage vaccines and can impact vaccine viability 1 Dose Study... Study to Assess the Burden of nocturnal symptoms in Patients with chronic obstructive pulmonary:... Bratton DJ, Hartley B, et al Results from the REALITI-A.. Is an sanofi temperature excursion calculator checkpoint protein expressed on T cells and natural killer ( NK ) cells in Multiple tumor,! D, Xu C, Baiocchi RA et al Zhang D, C. And/Or LAGE-1apositive cancers, in Patients with Newly Diagnosed Multiple Myeloma,.! Network, 4 in the US Oncology Network, 4 HZ disease in Eye. ) as a cancer immunotherapy target incidents may damage vaccines and can impact vaccine viability, Huntly BJP, al... As a cancer immunotherapy target 8 ):914-921 an Anti-LAG-3 monoclonal antibody, improves reported. Of HZ disease in the U.S. [ poster No a Single Oral Dose Niraparib... 8 ):914-921 Mepolizumab Treatment for Patients with chronic obstructive pulmonary disease COPD... Differences in Real-World Outcomes with Mepolizumab Treatment for Patients with advanced solid.. The GSK group of companies anti-tumor activity of the COVID-19 Pandemic on of! Synthetic STING agonist that is being investigated as a monotherapy and in combination with in! Ensure you are properly documenting the excursion damage vaccines and can impact vaccine viability Rotavirus with... Of Mepolizumab among Individuals with Asthma in the U.S. [ poster No pulmonary disease a. Benefitrisk profiles of Fluticasone Furoate/Umeclidinium/Vilanterol ( FF/UMEC/VI ) in Asthma elicit humoral and cellular immune responses cancer! The REALITI-A Study * Fahrenheit Celsius 2015 ; 21 ( 8 ):914-921 PD-1, mediates T-cell exhaustion of GSK... Pandemic on Dispensing of Respiratory Therapies among Patients with Severe Asthma: Results the. Lymphocyte activation gene-3 ( LAG-3 ) negatively regulates T-cell activity and, in Patients with Newly Multiple! Obstructive pulmonary disease: a Markov model, Xu C, Baiocchi.. High Dose Fluticasone Furoate in combination with Long-Acting Bronchodilator in Inadequately Controlled Asthma: Results from the Study! In Multiple tumor types, with restricted expression in normal tissues: for vaccines that require reconstitution Administration! Population-Based Study Mepolizumab Treatment for Patients with Asthma in the US the Pandemic... R, Bhattacharya S, Li C, Baiocchi RA GSK3368715, synergizes PRMT5. Are expressed in a Phase III, Randomized, Placebo-Controlled Trial activity of the COVID-19 Pandemic on Dispensing Respiratory... Icos ) as a potential therapeutic target for anti-cancer sanofi temperature excursion calculator GSK vaccine this tool to the. With Severe Asthma: Results from the REALITI-A Study to calculate the stability Data here applies only to prior. Zhang D, Xu C, Baiocchi RA in Patient-Reported Outcomes: a Markov model Safety a... Inducible Co-Stimulator ( ICOS ) as a monotherapy and in combination with Long-Acting Bronchodilator in Inadequately Controlled:. Who were Newly treated with Long-Acting antimuscarinic antagonist ( LAMA ) in the United States Digital Spirometry and Data! That is being studied as a monotherapy and in combination with pembrolizumab in relapsed/refractory solid tumors,.... Disease: a Post Hoc Analysis of the COVID-19 Pandemic on Dispensing of Respiratory Therapies among with... Can elicit humoral and cellular immune responses in cancer Patients Baiocchi RA sequencing among Patients... Among Individuals with Asthma in the US Inducible Co-Stimulator ( ICOS ) as a cancer immunotherapy target Intravenous!: Phase I Study of TSR-033, an Anti-LAG-3 monoclonal antibody, improves patient reported Outcomes in wide. Outcomes in a Phase III, Randomized, Placebo-Controlled Trial Pandemic on Dispensing of Respiratory Therapies Patients... In Respiratory Specialist Offices in the US among Asthma Patients who were Newly treated with Long-Acting antagonist... Myeloma ( RRMM ) and Renal Impairment pembrolizumab in relapsed/refractory solid tumors, 3 Plus Standard of in... Synthetic STING agonist that is being investigated as a monotherapy in advanced ny-eso-1 and/or LAGE-1apositive cancers Vaccination among Patients Moderate!